Protara Therapeutics, Inc. SEC filings TARA
Protara Therapeutics, Inc. has 809 filings in SEC EDGAR's recent list, going back to Apr 14, 2006. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 11, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-8 | Employee stock plan registration | Aug 11, 2026 | — |
| 424B5 | Prospectus supplement | May 28, 2026 | — |
| S-3 | Shelf registration | May 14, 2026 | — |
| 424B7 | Prospectus supplement | Mar 6, 2026 | — |
| 424B7 | Prospectus supplement | Feb 2, 2026 | — |
| 424B7 | Prospectus supplement | Dec 9, 2025 | — |
| 424B5 | Prospectus supplement | Dec 5, 2025 | — |
| 424B5 | Prospectus supplement | Dec 4, 2025 | — |
| S-8 | Employee stock plan registration | Aug 11, 2025 | — |
| 424B7 | Prospectus supplement | Apr 28, 2025 | — |
| S-8 | Employee stock plan registration | Mar 5, 2025 | — |
| 424B5 | Prospectus supplement | Dec 11, 2024 | — |
| 424B5 | Prospectus supplement | Dec 9, 2024 | — |
| S-8 | Employee stock plan registration | Aug 6, 2024 | — |
| 424B3 | Prospectus | May 9, 2024 | — |
| S-3 | Shelf registration | May 2, 2024 | — |
| S-8 | Employee stock plan registration | Mar 14, 2024 | — |
| S-3 | Shelf registration | Nov 3, 2023 | — |
| S-8 | Employee stock plan registration | Mar 8, 2023 | — |
| S-8 | Employee stock plan registration | Mar 9, 2022 | — |
| S-8 | Employee stock plan registration | Mar 11, 2021 | — |
| S-3 | Shelf registration | Dec 9, 2020 | — |
| 424B5 | Prospectus supplement | Sep 23, 2020 | — |
| 424B5 | Prospectus supplement | Sep 23, 2020 | — |
| S-3MEF | Registration statement | Sep 22, 2020 | — |
| 424B5 | Prospectus supplement | Sep 21, 2020 | — |
| 424B5 | Prospectus supplement | Sep 21, 2020 | — |
| S-3 | Shelf registration | May 14, 2020 | — |
| S-8 | Employee stock plan registration | Mar 31, 2020 | — |
| 424B3 | Prospectus | Feb 11, 2020 | — |
| S-3 | Shelf registration | Jan 30, 2020 | — |
| S-8 | Employee stock plan registration | Jan 15, 2020 | — |
| 424B3 | Prospectus | Dec 19, 2019 | — |
| S-4/A | Filing | Dec 18, 2019 | — |
| S-4/A | Filing | Dec 17, 2019 | — |
| S-4/A | Filing | Dec 5, 2019 | — |
| S-4 | Registration for a merger or exchange | Nov 7, 2019 | — |
| S-1 | Registration statement | Mar 14, 2019 | — |
| S-8 | Employee stock plan registration | Jan 3, 2019 | — |
| S-3 | Shelf registration | Dec 18, 2018 | — |
| 424B3 | Prospectus | Mar 14, 2018 | — |
| S-8 | Employee stock plan registration | Jan 4, 2018 | — |
| 424B3 | Prospectus | Aug 21, 2017 | — |
| S-3/A | Form s-3/a | Aug 14, 2017 | — |
| S-3 | Shelf registration | Aug 3, 2017 | — |
| 424B3 | Prospectus | Mar 16, 2017 | — |
| S-3/A | Form s-3/a | Dec 15, 2015 | — |
| S-3 | Shelf registration | Nov 12, 2015 | — |
| S-8 | Employee stock plan registration | Nov 25, 2014 | — |
| 424B4 | Prospectus | Oct 22, 2014 | — |
| S-1MEF | Filing | Oct 21, 2014 | — |
| S-1/A | Amended registration statement | Oct 7, 2014 | — |
| S-1 | Registration statement | Sep 16, 2014 | — |
Showing 53 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TARA (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1359931
- Former names
- Protara Therapeutics, Inc. (until Aug 13, 2026); ArTara Therapeutics, Inc. (until Apr 23, 2020); PROTEON THERAPEUTICS INC (until Dec 31, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.